Deep Medicine Acquisition Corp.
DMAQ · NASDAQ
12/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.20 | 0.00 | 0.00 |
| FCF Yield | -11.71% | -4.22% | -0.80% | 0.00% |
| EV / EBITDA | -16.24 | -6.47 | -246.72 | 0.00 |
| Quality | ||||
| ROIC | -18.07% | -3.87% | -0.31% | 0.00% |
| Gross Margin | 66.73% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.45 | 2.59 | 1.69 | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 0.00% | -48.51% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.14 | -0.32 | 1.08 | 0.00 |
| Interest Coverage | 0.30 | 0.00 | -55.85 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 3.10 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -0.25 | 0.00 | 0.00 | 0.00 |